By Fineline Cube CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard therapy.
Regulatory Milestone & Development Status
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Product | CT1190B (allogeneic CD19/CD20-targeted CAR-T cell therapy) |
| Indication | Relapsed/refractory large B-cell lymphoma post-second-line therapy failure |
| Approval Type | Clinical trial approval |
| Approval Date | August 7, 2026 |
| Platform Technology | THANK-u Plus allogeneic CAR-T platform |
| Current Trials | Investigator-initiated trials (IIT) ongoing for relapsed/refractory B-cell non-Hodgkin’s lymphoma |
Drug Profile & Technological Innovation
- Therapy Type: Allogeneic (off-the-shelf) CAR-T cell therapy
- Targets: Dual targeting of CD19 and CD20 antigens
- Platform: Developed using CARsgen’s proprietary THANK-u Plus platform
- Development Stage: Preclinical to Phase 1 transition with NMPA clinical trial approval secured
- Therapeutic Differentiation: Addresses critical unmet need in patients who fail multiple lines of standard therapy
Clinical Significance & Unmet Medical Need
Large B-cell lymphoma represents the most common form of non-Hodgkin’s lymphoma, with approximately 30-40% of patients experiencing relapse or refractory disease after initial treatment. Patients who fail second-line therapy face limited options and poor prognosis, with median overall survival often measured in months rather than years.
CT1190B’s allogeneic nature represents a significant advancement over autologous CAR-T therapies, which require complex manufacturing processes using the patient’s own cells and can take weeks to produce. The “off-the-shelf” approach enables immediate treatment availability, potentially improving outcomes for rapidly progressing patients who cannot wait for autologous product manufacturing.
Strategic Market Positioning
- Addressable Population: Estimated 8,000-12,000 annual R/R LBCL cases in China requiring third-line or later therapy
- Competitive Advantage: Dual CD19/CD20 targeting may reduce antigen escape resistance mechanisms observed with single-target CAR-T therapies
- Platform Validation: THANK-u Plus platform demonstrates CARsgen’s leadership in allogeneic CAR-T technology development
- Global Potential: Strong foundation for international regulatory submissions based on robust preclinical data
- Pipeline Synergy: Complements CARsgen’s existing autologous CAR-T portfolio with differentiated allogeneic approach
Development Strategy & Commercial Outlook
The ongoing investigator-initiated trials (IIT) for relapsed/refractory B-cell non-Hodgkin’s lymphoma provide valuable real-world data to inform the formal clinical development program. This dual-track approach accelerates learning while maintaining regulatory compliance for the formal NMPA-approved trial.
Allogeneic CAR-T therapies represent the next frontier in cellular immunotherapy, with potential to transform treatment paradigms by eliminating manufacturing delays, reducing costs, and expanding access to life-saving therapies for patients with aggressive hematological malignancies.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for CT1190B. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and manufacturing challenges inherent in cellular therapy development.-Fineline Info & Tech